To compare the progression risk and postoperative outcomes of image-guided tumor ablation versus surgical resection in patients with T1a renal cell carcinoma.
Key Findings:
No significant difference in progression risk between ablation and resection after adjustment for confounders.
Ablation associated with shorter hospital stays (median 0 days) compared to resection and nephrectomy (median 2 days).
Local recurrence rates were 2% for ablation, 1% for resection, and 0% for nephrectomy.
Distant metastasis rates were similar for ablation and resection (approximately 2%), while nephrectomy had a rate of 4%.
Patients undergoing ablation were older and had more comorbidities compared to those undergoing resection.
Interpretation:
Both ablation and surgical resection are effective treatment options for T1a renal cell carcinoma, with ablation offering advantages in terms of hospital stay and postoperative contacts.
Limitations:
Retrospective registry design may introduce selection bias and unmeasured confounding.
Missing tumor size data for many patients undergoing ablation.
Specific complication types not systematically recorded.
Conclusion:
Despite a higher local recurrence rate in the ablation group, overall progression rates remained low across all treatment modalities, supporting the effectiveness of both options for T1a renal cell carcinoma.
The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.
